Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

Diabetic Medicine

Volumn 21, Issue 8, 2004, Pages 859-866

  Tan, M H ^a   Johns, D ^a   Strand, J ^b   Halse, J ^c   Madsbad, S ^d   Eriksson, J W ^e   Clausen, J ^a   Konkoy, C S ^a   Herz, M ^a,f  

^a ELI LILLY AND COMPANY   (United States)

^b Oulun Diakonissalaitos   (Finland)

^c Betanien Medical Center   (Norway)

^d HVIDOVRE HOSPITAL   (Denmark)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Glibenclamide; Hyperglycaemia; Insulin resistance; Pioglitazone; Type 2 diabetes

Indexed keywords

AMINOTRANSFERASE; CHOLESTEROL; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; REPAGLINIDE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ATHEROGENESIS; BACKACHE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HEADACHE; HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFLUENZA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIMB PAIN; LIPID BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; RHINOPHARYNGITIS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 3843149515     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01258.x     Document Type: Article

References (38)

1. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000; 108: 15S-22S.
2. Lebovitz HE. Insulin secretagogues: sulfonylureas and meglitinides. In LeRoith D, Taylor SI, Olefsky JM eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000; 769-778.
3. Vosper H, Khoudoli G, Graham T, Palmer C. Peroxisome proliferator- activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 2002; 95: 47-62.
4. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24: 710-719.
5. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-1611.
6. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE, Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-423.
7. Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care 1998; 21: 1462-1469.
8. Grunberger G, Dole JF, Freed MI. Rosiglitazone monotherapy significantly lowers HbA1c levels in treatment-naive type 2 diabetic patients. Diabetes 2000; 49: A109.
9. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative centrifuge. Clin Chem 1972; 18: 499-502.
11. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2192.
12. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-2410.
13. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in ApoB-lipoprotein-depleted plasma (FER (HDL). Clin Biochem 2001; 34: 583-588.
14. Schrefer S, ed. Mosby's Guide to Physical Examination, 3rd edn. St. Louis, MO: Mosby-Year Book, Inc., 1995; 419.
15. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab 2000; 85: 4426-4433.
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
17. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
18. Yokoyama H, Emoto M, Fujiwara S, Motoyama K, Morioka T, Komatsu M et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 2003; 26: 2426-2432.
19. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S et al. A randomized, placebo-controlled, double-blind clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with Type 2 diabetes. Clin Ther 2003; 25: 1074-1095.
20. Pavo I, Jermendy G, Varkonyi T, Kerenyi Z, Gyimesi A, Shoustov S et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-1645.
21. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993; 137: 959-965.
22. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
23. Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 1998; 21: 810-816.
24. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. JAMA 1999; 281: 2005-2012.
25. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34: 356-361.
26. Reaven GM. Insulin resistance and its consequences: type 2 diabetes mellirus and coronary heart disease. In LeRoith D, Taylor SI, Olefsky JM eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia: Lippincott Williams & Wilkins, 2000; 604-615.
27. Winkler K, Friedrich I, Baumstark MW, Wieland H, März W. Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2002; 2: 143-148.
28. Grundy SM. The National Cholesterol Education Program (NCEP) - The National Cholesterol Guidelines in 2001, Adult Treatment Panel (ATP) III. Am J Cardiol 2001; 90: 11i-21i.
29. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/ HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001; 161: 2685-2692.
30. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
31. Miyazaki Y, Matsuda M, Defronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002; 25: 517-523.
32. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791.
33. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111: 10-17.
34. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000; 26: 98-106.
35. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disorders 2002; 2: 11-19.
36. Jick SS, Stender M, Myers MW. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents. Diabetes Care 1999; 22: 2067-2071.
37. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes mellitus. Diabetes 2003; 52: 1363-1370.
38. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.